---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-052600"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T21:35:43.353694+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable

## Summary
- No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
- Low infectivity of H3N2 challenge strain made virology data uninterpretable; enrollment to be extended.
- Company plans to submit protocol amendment to UK MHRA to extend enrollment and ensure adequate infection rates.
- CC-42344 showed favorable safety/tolerability, but low infection rate hindered antiviral data analysis.

## SEC filing metadata
- accession: 0001493152-24-052600
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/0001493152-24-052600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-052600
- JSON: https://secwatch.observer/filing/0001493152-24-052600.json
- Plain text: https://secwatch.observer/filing/0001493152-24-052600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.